Boston Scientific (NYSE:BSX) said yesterday that it’s planning a three-year restructuring program that’s slated to cost at least $200 million.
The Marlborough, Mass.-based medical device maker said it expects to maintain roughly the same number of workers, although there will be some churn as new jobs are created.
“[T]he company does expect some employee attrition and limited headcount reductions to result from these restructuring activities,” the company said in a regulatory filing.
